| Identification | Back Directory | [Name]
N-(6-Chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide dihydrochloride | [CAS]
1782573-78-7 | [Synonyms]
MLN120B.2HCl
MLN120B dihydrochloride
N-(6-Chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide dihydrochloride | [Molecular Formula]
C19H16Cl2N4O2 | [MOL File]
1782573-78-7.mol | [Molecular Weight]
403.26 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture | [solubility ]
DMSO : 16.67 mg/mL (37.91 mM; ultrasonic and warming and adjust pH to 8 with NaOH and heat to 80°C) | [form ]
Solid | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
ML 120B is a novel competitive inhibitor of ATP and i-kappa-kinase-2 (IKK2), key regulator in the survival, proliferation and apoptosis resistance of lymphoma cells. | [in vivo]
MLN120B (oral administration; 50 mg/kg; twice daily; 3 weeks) induces a reduction of shuIL-6R, marker of tumor growth, marker of tumor growth. It also leads to a rend toward prolonged survival in animals treated versus control[1].MLN120B (oral administration; 50 mg/kg; twice daily; 3 weeks) induces a reduction of shuIL-6R, marker of tumor growth, marker of tumor growth. It also leads to a rend toward prolonged survival in animals treated versus control[3]. | Animal Model: | SCID mice implanted with human fetal bone chips and then INA6 cells are directly injected into mice[1] | | Dosage: | 50 mg/kg | | Administration: | Oral administration; twice daily; 3 weeks | | Result: | Inhibited human multiple myeloma cell growth in vivo. |
| Animal Model: | Two-month-old female Lewis rats[2] | | Dosage: | 30 mg/kg, 10 mg/kg, 3 mg/kg, or 1 mg/kg | | Administration: | Oral administration; twice daily; 3 weeks | | Result: | Protected against bone and cartilage destruction in a rat model. |
| [storage]
Store at -20°C |
|
|